Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

Although most patients with myelofibrosis (MF) derive benefit from ruxolitinib, some are refractory, have a suboptimal response, or quickly lose their response. To identify genes that may predict response to ruxolitinib, we performed targeted next-generation sequencing (NGS) of a panel of 28 genes r...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Patel, Keyur P., Newberry, Kate J., Luthra, Rajyalakshmi, Jabbour, Elias, Pierce, Sherry, Cortes, Jorge, Singh, Rajesh, Mehrotra, Meenakshi, Routbort, Mark J., Luthra, Madan, Manshouri, Taghi, Santos, Fabio P., Kantarjian, Hagop, Verstovsek, Srdan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2015
Pynciau:
Myeloid Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4528066/
https://ncbi.nlm.nih.gov/pubmed/26124496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-03-633404
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg